Saudi Arabia Continuous Glucose Monitoring Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Application (Diabetic Patients, Critical Patients), And By End User Industry (Hospitals, Diagnostic Centers And Clinics, Home Care) - Forecasts From 2023 To 2028

  • Published : Apr 2023
  • Report Code : KSI061614945
  • Pages : 105

The Saudi Arabia CGM market is expected to grow at a CAGR of 15.87%, from an initial value of US$ 8.227 million in 2021 to US$23.215 million by 2028.

Continuous sugar monitoring (CGM), sometimes referred to as sugar continuous glucose monitoring, automatically monitors blood glucose throughout the day. Making more educated choices about maintaining daily medication use, a healthy diet, and physical activity can be aided with real-time glucose monitoring. A small sensor used in CGM is implanted beneath the skin, often on the arm or abdomen. The sensor picks up interstitial glucose, which is present in the intercellular fluid. The sensor examines the glucose level every few minutes, and wireless data transmission sends the results to a monitor.

Moreover, the closed-loop bionic/artificial pancreas has been given a blueprint because of CGMS-based technologies. Thus, businesses that manufacture glucose monitoring devices concentrate largely on creating novel and cutting-edge CGMS. It has several applications for healthcare settings (hospital ICUs, diagnostic centers, and clinics), for all age groups, and geographical locations. A growing awareness of diabetes preventative care, new product debuts, government efforts, and the CGM device market are the major market drivers for CGM Market.

The market for diabetic devices in Saudi Arabia was dominated by the SMBG devices sector. Depending on the kind of diabetes, glucose levels must be checked often. In Saudi Arabia, there is a growing awareness of the benefits of self-monitoring glucose levels, and the market for monitoring devices is anticipated to expand rapidly. Current CGM systems provide a more accurate depiction of blood glucose patterns and trends than what is possible with the traditional method of routinely measuring glucose levels at predetermined intervals. Because of technological breakthroughs like the recently authorized non-invasive glucose meter, the use of CGM devices is on the rise in Saudi Arabia.

Increasing prevalence of diabetes to surge the market for CGM in Saudi Arabia.

One of the biggest health issues in Saudi Arabia is diabetes. In terms of the prevalence of diabetes, this nation is included among the top 10 globally. The primary risk factors for diabetes include obesity, particularly central obesity, and increased visceral fat from physical inactivity, as well as the eating of high-calorie, high-fat, and high-sugar meals. The most prevalent work culture in the nation, which promotes eating fast food with little to no exercise and sitting still for extended periods, is a major cause of diabetes in people of working age.

Growing awareness of monitoring devices to surge the growth.

The frequency of checking blood sugar levels is determined by the kind of diabetes each patient has, which varies. In Saudi Arabia, where self-monitoring of blood glucose levels has become much more popular, the market for monitoring devices is anticipated to rise rapidly throughout the projected period. The modern CGM systems eliminate all finger pricking for blood glucose monitoring. It provides a more accurate depiction of blood glucose patterns and tendencies than is possible with traditional regular testing of glucose levels at predetermined intervals.

Market Key Developments

  • In April 2023, the French healthcare corporation Sanofi and the Saudi Health Council have signed a memorandum of understanding to work together on research and development projects about diabetes in the Kingdom.
  • In March 2022, the largest port in Saudi Arabia, Jeddah Islamic Port, will soon house a 130,000 square meter specialized container depot and warehouse thanks to a contract that CMA CGM Group has signed with the Saudi Ports Authority (SPA) (JIP).


  • By Application
    • Diabetes Patients
    • Critical Patients
  • By End-User Industry
    • Hospitals
    • Diagnostic Centers & Clinics
    • Home Care


1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline


2.1. Research Data

2.2. Assumptions


3.1. Research Highlights


4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis


5.1. Introduction

5.2. Diabetes Patients

5.3. Critical Patients


6.1. Introduction

6.2. Hospitals

6.3. Diagnostic Centers & Clinics

6.4. Home Care


7.1. Major Players and Strategy Analysis

7.2. Emerging Players and Market Lucrativeness

7.3. Mergers, Acquisitions, Agreements, and Collaborations

7.4. Vendor Competitiveness Matrix


8.1. Abbott Laboratories

8.2. Medtronic plc

8.3. Dexcom, Inc.

8.4. Roche Diabetes Care, Inc.

8.5. Sanofi

8.6. Insulet Corporation

8.7. Ypsomed AG

8.8. Novo Nordisk A/S

8.9. Becton, Dickinson, and Company

8.10. Tandem Diabetes Care, Inc.

Abbott Laboratories

Medtronic plc

Dexcom, Inc.

Roche Diabetes Care, Inc.


Insulet Corporation

Ypsomed AG

Novo Nordisk A/S

Becton, Dickinson, and Company

Tandem Diabetes Care, Inc.